415 related articles for article (PubMed ID: 28590343)
1. Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study.
Kopylov U; Papamichael K; Katsanos K; Waterman M; Bar-Gil Shitrit A; Boysen T; Portela F; Peixoto A; Szilagyi A; Silva M; Maconi G; Har-Noy O; Bossuyt P; Mantzaris G; Barreiro de Acosta M; Chaparro M; Christodoulou DK; Eliakim R; Rahier JF; Magro F; Drobne D; Ferrante M; Sonnenberg E; Siegmund B; Muls V; Thurm T; Yanai H; Dotan I; Raine T; Levin A; Israeli E; Ghalim F; Carbonnel F; Vermeire S; Ben-Horin S; Roblin X
Inflamm Bowel Dis; 2017 Sep; 23(9):1605-1613. PubMed ID: 28590343
[TBL] [Abstract][Full Text] [Related]
2. Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis.
Nelson R; Liao C; Fichera A; Rubin DT; Pekow J
Inflamm Bowel Dis; 2014 Jan; 20(1):14-20. PubMed ID: 24297054
[TBL] [Abstract][Full Text] [Related]
3. Similar Short- and Long-term Colectomy Rates with Ciclosporin and Infliximab Treatment in Hospitalised Ulcerative Colitis Patients.
Duijvis NW; Ten Hove AS; Ponsioen CI; van den Brink GR; Buskens CJ; Bemelman WA; Te Velde AA; D'Haens GR; Löwenberg M
J Crohns Colitis; 2016 Jul; 10(7):821-7. PubMed ID: 26818660
[TBL] [Abstract][Full Text] [Related]
4. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants.
Yoshino T; Nakase H; Matsuura M; Matsumura K; Honzawa Y; Fukuchi T; Watanabe K; Murano M; Tsujikawa T; Fukunaga K; Matsumoto T; Chiba T
Digestion; 2011; 84(1):3-9. PubMed ID: 21311190
[TBL] [Abstract][Full Text] [Related]
5. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study.
Sjöberg M; Walch A; Meshkat M; Gustavsson A; Järnerot G; Vogelsang H; Hertervig E; Novacek G; Friis-Liby I; Blomquist L; Angelberger S; Karlen P; Grännö C; Vilien M; Ström M; Verbaan H; Hellström PM; Dejaco C; Magnuson A; Halfvarson J; Reinisch W; Tysk C
Inflamm Bowel Dis; 2012 Feb; 18(2):212-8. PubMed ID: 21438096
[TBL] [Abstract][Full Text] [Related]
6. Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis.
Shah SC; Naymagon S; Panchal HJ; Sands BE; Cohen BL; Dubinsky MC
Inflamm Bowel Dis; 2018 Feb; 24(3):651-659. PubMed ID: 29462380
[TBL] [Abstract][Full Text] [Related]
7. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis.
Löwenberg M; Duijvis NW; Ponsioen C; van den Brink GR; Fockens P; D'Haens GR
Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1240-6. PubMed ID: 25171024
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study.
Mocciaro F; Renna S; Orlando A; Rizzuto G; Sinagra E; Orlando E; Cottone M
J Crohns Colitis; 2012 Jul; 6(6):681-6. PubMed ID: 22398101
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of the Burden of Cytomegalovirus Colonic Reactivation Evaluated by Immunohistochemical Staining in Patients with Active Ulcerative Colitis.
Clos-Parals A; Rodríguez-Martínez P; Cañete F; Mañosa M; Ruiz-Cerulla A; José Paúles M; Llaó J; Gordillo J; Fumagalli C; Garcia-Planella E; Ojanguren I; Cabré E; Guardiola J; Domènech E
J Crohns Colitis; 2019 Mar; 13(3):385-388. PubMed ID: 30346606
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of inflammatory bowel diseases with cytomegalovirus colitis: effect of antiviral treatment.
Maconi G; Lombardini M; Furfaro F; Bezzio C; Zerbi P; Ardizzone S
Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1146-51. PubMed ID: 25089547
[TBL] [Abstract][Full Text] [Related]
11. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
[TBL] [Abstract][Full Text] [Related]
12. Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study.
Kim EH; Kim DH; Park SJ; Hong SP; Kim TI; Kim WH; Cheon JH
Gut Liver; 2015 Sep; 9(5):601-6. PubMed ID: 25473080
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status.
Inokuchi T; Kato J; Hiraoka S; Suzuki H; Nakarai A; Hirakawa T; Akita M; Takahashi S; Harada K; Okada H; Yamamoto K
World J Gastroenterol; 2014 Jan; 20(2):509-17. PubMed ID: 24574719
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.
Filippi J; Laharie D; Michiels C; Flamand M; Bouguen G; Nancey S; Presles E; Paul S; Schneider S; Hébuterne X; Roblin X
J Crohns Colitis; 2015 Mar; 9(3):252-8. PubMed ID: 25588386
[TBL] [Abstract][Full Text] [Related]
15. Long-term comparative efficacy of cyclosporine- or infliximab-based strategies for the management of steroid-refractory ulcerative colitis attacks.
Naves JE; Llaó J; Ruiz-Cerulla A; Romero C; Mañosa M; Lobatón T; Cabré E; Garcia-Planella E; Guardiola J; Domènech E
Inflamm Bowel Dis; 2014 Aug; 20(8):1375-81. PubMed ID: 25046008
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients.
Matsuoka K; Iwao Y; Mori T; Sakuraba A; Yajima T; Hisamatsu T; Okamoto S; Morohoshi Y; Izumiya M; Ichikawa H; Sato T; Inoue N; Ogata H; Hibi T
Am J Gastroenterol; 2007 Feb; 102(2):331-7. PubMed ID: 17156136
[TBL] [Abstract][Full Text] [Related]
17. High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival.
Chao CY; Al Khoury A; Aruljothy A; Restellini S; Wyse J; Afif W; Bitton A; Lakatos PL; Bessissow T
Dig Dis Sci; 2019 Feb; 64(2):518-523. PubMed ID: 30446928
[TBL] [Abstract][Full Text] [Related]
18. Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis.
Leblanc S; Allez M; Seksik P; Flourié B; Peeters H; Dupas JL; Bouguen G; Peyrin-Biroulet L; Duclos B; Bourreille A; Dewit O; Bouhnik Y; Michetti P; Chaussade S; Saussure P; Mary JY; Colombel JF; Lémann M;
Am J Gastroenterol; 2011 Apr; 106(4):771-7. PubMed ID: 21386832
[TBL] [Abstract][Full Text] [Related]
19. Unfavorable outcome of antiviral therapy in cytomegalovirus-positive ulcerative colitis may be due to inappropriate study inclusion in meta-analysis.
Wu XW; Yang MF; Li N; Wang FY
World J Gastroenterol; 2015 Feb; 21(5):1689-90. PubMed ID: 25663793
[TBL] [Abstract][Full Text] [Related]
20. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis.
Dean KE; Hikaka J; Huakau JT; Walmsley RS
J Gastroenterol Hepatol; 2012 Mar; 27(3):487-92. PubMed ID: 22098019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
